Drug intelligence / Profile preview

scFv-FrC

Development stage: Unknown
Lead developer: University of Southampton
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

scFv-FrC is a patient-specific DNA fusion vaccine designed for the treatment of multiple myeloma. It encodes a fusion protein comprising a tumor-derived single chain variable fragment (scFv), which represents the tumor-specific idiotype (Id), linked to fragment C (FrC) of tetanus toxin. The vaccine aims to induce Id-specific T-cell and antibody responses, with FrC serving as an immune alert signal to enhance the overall immunological response against the myeloma cells. It was developed by researchers at the University of Southampton and University of Bristol.

Targets

Id (Tumor-specific idiotype immunoglobulin)

Beyond the preview

Go deeper on scFv-FrC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on scFv-FrC.

Explore the full profile